Abbott Laboratories
ABT
$113.63
$0.020.02%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.42% | 6.90% | 7.37% | 3.95% | 7.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.42% | 6.90% | 7.37% | 3.95% | 7.16% |
| Cost of Revenue | 0.68% | 8.02% | 5.45% | -0.18% | 8.44% |
| Gross Profit | 7.42% | 6.01% | 8.90% | 7.31% | 6.15% |
| SG&A Expenses | 7.82% | 5.18% | 5.29% | 2.79% | 50.14% |
| Depreciation & Amortization | -9.25% | -10.64% | -10.83% | -11.02% | -3.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.83% | 6.05% | 4.38% | 0.45% | 22.06% |
| Operating Income | 18.77% | 10.58% | 21.57% | 23.45% | -49.09% |
| Income Before Tax | 16.16% | 12.37% | 33.79% | 23.82% | 13.09% |
| Income Tax Expenses | 108.08% | 82.31% | 21.64% | 114.69% | -3,681.59% |
| Earnings from Continuing Operations | -80.76% | -0.12% | 36.64% | 8.16% | 478.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.76% | -0.12% | 36.64% | 8.16% | 478.98% |
| EBIT | 18.77% | 10.58% | 21.57% | 23.45% | -49.09% |
| EBITDA | 10.01% | 7.19% | 13.85% | 13.22% | -35.80% |
| EPS Basic | -81.02% | -0.27% | 36.60% | 8.23% | 481.70% |
| Normalized Basic EPS | 12.72% | 12.19% | 22.82% | 26.27% | 6.15% |
| EPS Diluted | -80.95% | 0.00% | 36.49% | 8.57% | 479.43% |
| Normalized Diluted EPS | 12.72% | 12.27% | 22.88% | 26.35% | 6.15% |
| Average Basic Shares Outstanding | 0.06% | 0.15% | 0.02% | -0.06% | -0.11% |
| Average Diluted Shares Outstanding | 0.06% | 0.10% | -0.02% | -0.14% | -0.11% |
| Dividend Per Share | 6.78% | 7.27% | 7.27% | 7.27% | 7.27% |
| Payout Ratio | 4.59% | 0.08% | -0.22% | -0.01% | -0.81% |